This is the authors' abstract. We don't add key points for this paper.
Extracellular HSP90α (eHSP90α) is a promoter of tumor development and malignant progression. Patients with malignancies, including pancreatic ductal adenocarcinoma (PDAC), have generally shown 5~10-fold increases in serum/plasma eHSP90α levels. In this study, we developed a humanized antibody HH01 to target eHSP90α and evaluated its anticancer efficacy. HH01, with novel complementarity-determining regions, exhibits high binding affinity toward HSP90α. It recognizes HSP90α epitope sites
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Fan et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: